---
title: "United Therapeutics beat Q4 earnings estimate with $7.70 earnings per share. Sales were $790.200 million, missing estimate. CEO is optimistic about future clinical programs."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277086841.md"
description: "United Therapeutics Corp (NASDAQ: UTHR) reported Q4 earnings of $7.70 per share, exceeding estimates of $7.09. However, sales of $790.200 million fell short of the expected $813.077 million. CEO Martine Rothblatt expressed gratitude for the record revenue achieved for the fourth consecutive year and is optimistic about upcoming clinical programs, ADVANCE OUTCOMES and TETON-1, which may offer new treatment options for patients."
datetime: "2026-02-26T18:58:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277086841.md)
  - [en](https://longbridge.com/en/news/277086841.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277086841.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277086841.md) | [繁體中文](https://longbridge.com/zh-HK/news/277086841.md)


# United Therapeutics beat Q4 earnings estimate with $7.70 earnings per share. Sales were $790.200 million, missing estimate. CEO is optimistic about future clinical programs.

United Therapeutics Corp (NASDAQ: UTHR) exceeded expectations in their fourth-quarter earnings report, revealing earnings of $7.70 per share, surpassing the estimated $7.09 per share. However, the company fell short of the projected $813.077 million in quarterly sales with reported sales totaling $790.200 million. Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, expressed gratitude towards the team for achieving record total revenue for the fourth consecutive year. The company is eagerly anticipating the results of their ADVANCE OUTCOMES and TETON-1 clinical programs which have the potential to introduce new treatment alternatives for patients.

### Related Stocks

- [United Therapeutics Corporation (UTHR.US)](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [United Therapeutics Insider Sold Shares Worth $5,006,100, According to a Recent SEC Filing](https://longbridge.com/en/news/281244311.md)
- [United Therapeutics Insider Sold Shares Worth $786,032, According to a Recent SEC Filing](https://longbridge.com/en/news/281244273.md)
- [Assenagon Asset Management S.A. Buys 3,824 Shares of United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/280868172.md)
- [United Therapeutics Director Sold Shares Worth Over $1.0M](https://longbridge.com/en/news/280686000.md)
- [These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings](https://longbridge.com/en/news/277085456.md)